Endpoints NewsOriginal article
Novartis' TREM2 drug fails Phase 2 ALS trial
Phase 2negativeVHB937/lifonebartNegative
AI Analysis
Summary
Novartis has discontinued development of VHB937/lifonebart (TREM2 inhibitor) following a Phase 2 trial failure in amyotrophic lateral sclerosis.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Not Met
Outcome Details
Phase 2 ALS trial failed; development discontinued
Importance:6/10
Sentiment:
-0.90
Phase 2 failureALSTREM2program discontinuation
Related Companies
Read the original article
Published by Endpoints News on September 16, 2026 11:24 AM